Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-23-043975

Chief Scientific Officer sold 1,884 shares at $9.65 ($18,189)

  • Chief Scientific Officer acquired 5,207 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Hansen Gwenn · Chief Scientific Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-07-30 Exercise or conversion : show line 1 in the form +3,207 29,839 D
2023-07-30 Exercise or conversion : show line 2 in the form +2,000 31,839 D
2023-07-31 Sale : show line 3 in the form −1,884 $9.65 $18,189 29,955 D
Open-market sales · 1,884 sh · avg $9.65 · $18,189

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2023-07-30 Exercise or conversion : show line 4 in the form Restricted Stock Units −3,207 32,068 D
2023-07-30 Exercise or conversion : show line 5 in the form Restricted Stock Units −2,000 22,000 D
Loading xslF345X05/doc4.xml…